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Abstract: 
To describe the fibronectin molecu1e and its role in the metastatic process of cancer. To 
also show the rational behind the structure and the \vay it was reasoned. To define the method of 
development for RGD inhibitory molecu1e through kno\vledge of past experiments and 
conclusions. Substituting various amino acid residues into fibronectin 1ike molecules to 
understand the effect each residue has in the overall stereochemistry and electrochemistry of the 
fibronectjn binding site. Outlining a synthesis for one of more effective inhibiting peptide and the 




Cancer is one of the leading killers in the industrialized nations. It stems from one 
initial growth and then spreads throughout the body to overwhelm the immune system and 
destroy the systems invaded. Cancers have a metastatic ability, and it is this ability that 
causes most cancer deaths 1. If cancers consisted only of primary tumors, then most could 
be removed surgically or treated with drugs or other chemicals; however, cancers have an 
ability to move from one area to other unrelated areas of the body and start new growths. 
If the metastatic process could be slowed, or better yet halted, then a huge advancement in 
medical science would be made. 
Cancer Metastasis 
The metastatic process will be broken down into seven steps for simplicity. It 
should be noted that these steps are not always independent of one another and may occur 
simultaneously within the organism. These breakdowns are merely used to make each 
process more understandable; it is worth noting that if any of these steps are halted, then 
no secondary growth forms. 
A neoplasm of unknown origin (see Figure 1) has some sort of initial (la) local 
--
invasion, the cancerous cells must penetrate the neighboring tissue of the neoplasm. After 
leaving the neoplasm's environment, the cancerous cells must (1) detach from the primary 
tumor and survive. The cells may do this either as indivdually or as larger groupings of 
cells. In order for a dissemination of the metastic cells, the transformed cells must (2) 
invade local blood vessels and be (3) transported to other areas of the body via the 
circulatory system. The cells moving in the blood stream then must (4) lodge into the 
blood vessel wall. Experimentally, it has been shown that the arrest occurs most often in 
the capillary beds; it is assumed that arrest does not occur often in the larger vessels due to 
1 
I 
blood shearing forces that the cells would encounter. The cells lodge at sites distal from 
the primary tumor in three ways, not always independent of one another. The cells may 
become physically lodged in a blood vessel or capillary bed due their size versus that of the 
vessel. Malignant cells may also adhere to blood vessel walls through a specific 
recognition. Experimentally, it has not been shown that malignant cells have an exclusive 
mechanism with any specific cell type; however, the cells may display selective adhesion 
to the blood vessel endothelium of certain organs. The lodgment occurs due to molecular 
interactions between the surfaces of the malignant cell and the vessel wall; however, the 
interactions are not exclusive of either adhering cells' surfaces, but rather selective for the 
surfaces. Once the malignant cells are lodged on the vessel wall, (5) extravasation of the 
malignant cell out of the circulatory system occur and the transformed cells migrate to a 
secondary site. Once migration is complete, continued (6) growth 2 must occur. 
Figure 1 The Metastatic Process as described above2 
2 
Fibronectin and the Fibronectin Receptor 
Fibronectin is a 440 kD extra cellular matrix protein identified important in the 
selective attachment step of the metastatic process. Fibronectin is composed of two similar 
polypeptide chains linked via a disulfide bridge near the carboxyl terminals. Fibronectin is 
important in the secondary growth of cancer, because it provides an attachment site for the 
transfonned cells free floating in the circulatory system. Fibronectin has a major binding 
site composed of a three amino acid sequence. Through competitive inhibition, the 
Arginine-Glycine-Aspartic Acid-(Serine), also known as the RGD(S) sequence, has been 
proposed to compose the selective binding site.2 
The fibronectin receptor is glycoprotein complex composed of an alpha and beta 
subunit, 150 kD and 130 kD, respectively. The fibronectin receptor itself is extremely 
variable with as many as ten alpha subunits and eight beta subunits. The variability allows 
the intergrin the ability to be apart of many cellular functions. 3 This variability makes the 
study of the receptor difficult, so the vast majority of the research is focused on the 
fibronectin itself. 
Gaining Understanding of the RGD-Adhesion Site 
Through experimentation, a smaller 75 kD peptide subunit containing the RGDS 
sequence has the ability to adhere moderately to the transfonned cells, while a smaller 11.5 
kD peptide fragment containing the RGDS fragment is not very effective in its adherence. 
From this observation fibronectin was proposed to have two, maybe even three, distinct 
binding sites for its adherence to metastatic cells.4 
Trigramin, a snake venom, contains the RGD peptide and inhibits the attachment of 
transfonned cells to fibronectin. From this it was deduced that the concept of two or three 
binding sites is faulty. The snake venom inhibits attachment yet it shares no relationship 
with adhesion molecules other than the RGD site. When the trigramin was reduced 
chemically, there was a loss of inhibitory effect, suggesting the secondary structure of 
trigramin was important in its binding abilities to the fibronectin receptor. It was shown 
3 
that the trigramin had a larger effect on adhesion than the straight ORODS chain, and the 
/ ORODS chain had a larger effect than that of the reduced trigramin.5 
Table 1 The effect of trigramin on the adhesion of C32 melanoma cells to fibronectin a 
Treatment Concentration 
1. No peptide 
2. Trigramin 0.11 J..LM 
3. Reduced trigramin 0.55 J..LM 
4. ORODS 50 J..LM 
Adherent cells 
386 +/- 60 
55 +/- 26 
299 +/- 60 






aThe method of adhesion assay and value determinations are referenced in Knudsen, et.al.5 
Predictions of the location of the RODS adhesion site gives insight into the possible 
secondary structure of the attachment donlain. Located in a hydrophilic portion of the 
attachment domain, the RGDS sequence may form a B- tum at a hydrophilic loop at the 
surface of the molecule. At this external position, the RODS structure is available to 
interact with cell surfaces.6 The integrity of the RODS sequence has to be maintained to 
insure activity of the peptide. If the arginine or the aspartic acids are deleted from the 
sequence, the activity is lost. The activity is also lost if the peptide is cleaved at the 
arginine, or if the glycine is substituted by a bulky valine residue. Deletions or cleavages 
cause a shift on the hydrophilic loop and other changes of secondary structure are expected 
4 
from the shift. 7 It is noted that a glycine substitution causes a loss of activity without 
,/ shifting the sequence. 
Figure 2 Prediction of secondary structure of 11.5 kD cell attachment domain of 
fibronectin with attachment signal in a.B turn hydrophilic loop (boxed region).? 
1 ' ....... 
. Several synthetic peptides attached to protein coated plastic beads were tested for 
their adhesion inhibiting effect. All molecules that inhibited attachment had the RGDS 
segment, and larger molecules generally had greater inhibitory ability. The decreased 
activity with decreased size may be due to decreased stability of the smaller molecule or to 
the small molecule's inability to access the substrate. The RGDS straight chain tetrapeptide 
was attached to Sepharose beads at the end of a C6 spacer arm; however, there was no 
5 
inhibitory activity displayed. Again, the small size may have limited accessibility, but also 
/' the coupling method may not be efficient.? 
In other experiments, inhibition of cell attachment did not occur with soluble 
fibronectin or with attainable concentrations with a 30 amino acid sequence. It is 
presumed to be the low affinity of a single fibronectin molecules to cell surfaces. Large 
concentrations of the soluble fibronectin fragments are needed to overcome the interactions 
of extra cellular matrix fibronectins. Smaller more highly soluble peptides are more likely 
to have activity at lower concentrations because less interaction takes place between the 
fibronectin fragments and the extra cellular matrix fibronectin.7 However, testing many 
different sequences and cOlnbinations of sequences show that poly (RGD) molecules have 
the higher activity on weight basis in the inhibition of adhesions than the oligo peptide or 
the monomer.8 CD spectra analysis determined the poly(RGD) sequence is a more 
ordered sequence than oligo(RGD) or poly(R,G,D), with the sequence of R,G,D being 
repeatedly rearranged. The CD spectra analysis using a computer program of Chang et.al. 
determined the sequence structure using an average helical segment of 11 residues. The 
poly(RGD) molecule has the most B-tums, with B-tums being predicted in all poly(RGD) 
regions; thus giving the poly(RGD) sequence the secondary structure most favored by the 
fibronectin receptor.6 
A crystal structure has been determined of an OPG2 Fab molecule with a RYD 
adhesion site that ~mics the RGD adhesion site. The entire molecule consists of two 
protein strands with 214 and 227 amino acids, respectively.9 From this structure, further 
study of the binding site and future inhibitor development may follow. The OPG2 Fab 
molecule is not fibronectin, rather it is a mouse immunoglobulin that shares a similar 
binding site with fibronectin and other adhesion molecules. The adhesion site in the Fab 
molecule is an arginine-tyrosine-aspartic acid (RYD) sequence, yet it mimics the RGD 
sequence found in adhesion molecules. From previous experiments, the structure of the 
sequence has proven to be extremely important in the activity of the molecule. The OPG2 
6 
Fab molecule presents a clear crystalline structure of the binding site, conformation, and 
secondary structure. to The resolution of the Fab molecule is 2 A considered to be 
impressive for a molecule of this size. The structure of the OPG2 Fab molecule (Figure 3 
and Figure 4) was acquired from the Protein Data Bank at the Brookhaven National 
Laboratory, Upton, New York.9 The structure was displayed using Sybyl Molecular 
Modeling Software, version 6.2 Beta, 1995 (Tripos Associates, Inc., St. Louis, Missouri 
63144) on a EVS workstation (Evans and Suthreland, Salt Lake City, Utah). 
The following is a detailed view of the specific RYD binding site. The binding site 
has a tyrosine that replaces the glycine of the RGD sequence; however, the backbone 
stereochemistry of the site is much more important than the effects of the replacement. As 
can be noted from Figure 3 the RYD binding site is on the external surface of the molecule 
with little other steric hindrances in close proximity to the site. Figure 4 closely 
demonstrates the openness of the binding site, as well as the extreme stereoselectivity of the 
binding site. It can also be noted the pocket behind the R YD sequence open for binding. 
From this OPG2 Fab crystalline structure, a more directed development of adherence 
inhibitors may be synthesized in conjunction with other experimental data and molecular 
modeling. 
7 
Figure 3 OPG2 Fab Mouse Immunogloblin with RYD sit~Lhat mlmlCS 
RGD site 0f adhesion molecules 
a 
attained fran Protein Data Bank;! Brookhaven National 




RYD binding site of OPG2 Fab Mouse Immunogloblin 
attained from Protein Data Bank, Brookhaven National 
Laboratory, Upton, New York. 
Specific Stereoselective Synthesis 
From previous data and knowledge, specific synthetic peptide have been proposed for 
development. To test the stereochemistry of the binding site, a ROD peptide was 
synthesized with the residues following the aspartic acid (D) being varied to detect the 
contribution of each. In the primary ROD sequence the L forms of each amino acid were 
substituted with their D forms to test the structure stereoselectivity at the binding site. 
Finally a peptide sequence underwent cyclicazation to prevent flexibility hoping that the 
affinity of the entire molecule might be increased by a strict conformation. Various 
residues following the main binding domain in the cyclic ROD were tested, and different 
activities were noted from each; thus leading to the conclusion that residues following the 
RGD sequence influence the stereochemistry of the RGD backbone segment itself. From 
the cyclic molecule, the greatest specificity and adhesive ability was noted. The greater 
activity was noted from the less flexible conformation, the more stable and specific RGD 
sequence. I I 
Through specific synthesis for a cyclic pentapeptide, a B- turn was by changing one 
of the amino acid residues from a L conformation to that of a D conformation with internal 
stabilization coming from hydrogen bonding within the peptide backbone. 12 As shown by 
contrasting Figure 5 and Figure 6, the importance of an amino acid exchanging the L 
conformation for the D conformation is shown. In Figure 6 there are not the double 
hydrogen bonding and no B-turn as demonstrated in Figure 5. 
10 
F~gure 5 RGDFV cyclic amino acid with all residues in L 
conformation except the Phe (F) groupn 
1 1 
Figure 6 RGDFV cyclic amino acid wi th all residues in L ;'O::J 
conformations 
view 1 view 2 
1 2 
Using molecular dynamic simulations, Gurrath et al.(13) refined the pentapeptide 
/' synthesis to also include hexapeptide analogues to describe more comprehensively the 
structure/activity relationship. Cyclic molecules are used to introduce conformational 
constraints required of receptor binding and activity; six membered rings are synthesized to 
test their inhibitory activity versus those of the tested five member cyclic rings. It was 
found that the six membered rings were less active and less selective than the five member 
cyclicpeptide. The correlation between structure and activity indicate that it was ring 
contraction, not the position of the RGD section in a hydrophilic loop, that increased the 
affinity for adhesion.13 RGD positioning within the fibronectin's B-tum no longer 
explained the importance of the cyclic compound, rather ring contraction appears to be 
important. Again both conclusions validate one another to a degree; however, the work of 
Gurrath showed that simply a tum was not the only requirement needed to synthesize an 
effective inhibitor. 
Through experimentation and various substitution, the positive and negative side 
chains of the arginine and aspartic acid are found to be necessary functionalities for 
binding. Equally important is the unmodified glycine spacer amino acid. 13 Shown in 
Figure 7, positive and negative charges are needed for strong affinity to the receptor site. 
Glycine is important to the binding capability of the RGD sequence, since a large side chain 
from the glycine position may cause receptor repulsion in a streically demanding binding 
pocket. A narrow- binding cleft is postulated and any large substituents would not allow 
tight binding, if binding occurs at all. All steric modifications of the arginine or aspartic 
acid lead to reduced binding efficiencies. Some studies have shown the ability to bind such 
molecules, yet this binding is probably due to a compensation of the torsional freedom in 
the amino acid side chains themselves. 
Figure i Electrical and steric requirements for binding 14 
Yaa6 
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-' Synthesis of cyclic RGDnFV pentapeptide 
The synthesis was carried out on a Sasrin® resin solid phase using 4-methoxy-
2,3,6-trimethylbenzenesulfonyl (Mtr) as the arginine guanidino function protecting group, 
and t-butyl ester as the aspartic acid.tfte side chain protector. No other protectors are 
needed for the remaining side chains. 
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In the synthesis the washings are important to insure that the peptide is made up of 
only added material not of any waste material from previous steps. The fIrst step of the 
synthesis is two washings for three minutes with HCONMe2, (N,N-dimethylformamide). 
The second step is prewashing in 20% piperidine in HCONMe2 for three minutes also. A 
deprotection of the amino acid derivative is carried out in 20% piperidine in HCONMe2 
once allowing the reaction to proceed for fifteen minutes, followed by ten, three minute 
washings in HCONMe2. 
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The coupling of the amino acid is four moles ofFmoc (9-fluorenylmethoxycarbonyl) 
/' protected amino acid derivative, and one mole of the coupling reagent of 1,3-
dicyclohexy1carbodiimide I-hydroxybenzotriazole, with C4H60NMe (1-methyl-2-
pyrrolidinone) as the basic component in EtN(iPr)2 (N,N-diisopropylethylamine). It is 
allowed to react for apRroximately forty minutes. ~ 
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This is followed by ten, three minute washings in HCONMe2 followed by two, three 
minute washings in dichloromethane. The entire procedure is repeated until the length of 
the chain is produced. The chain is cleaved from the resin using 1 % trifluoroacetic acid in 
dichloromethane (1: 1 :3). Under these conditions the side chain protecting groups are 
stable. 
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The cyclicazation was performed in N,N-dimethylformamide with 1.5 moles of amino acid 
chain in one mole diphenlyphosphory I azide at high dilution for four days. 
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/' The pH was maintained at 8.5- 9.0 by additions of triethylamine. The side chain protecting 
groups were removed with trifluoroacetic acid and a scavenger of 5% p-thiocresol. 
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The peptide was purified in high performance liquid chromatography with a reverse phase 
C18 3-Jlm material using a gradient ofwater/CH3CN/trifluoroacetic acid (95 : 5 : 0.2 to 
20 : 80 : 1.0) over a fifteen minute period. The peptides were characterized by fast atom 
bombardment mass spectroscopy, amino acid analysis and various NMR techniques. 13 
Future Developments 
With continued work and development, cyclic pentapeptides may have a place in 
cancer treatment one day. Further refmement of the binding site stereochemistry is 
important, as well as, the fragments' affinity to the fibronectin receptors of the cancer cells. 
17 
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